The
following table presents the number of shares subject to outstanding stock options, warrants, and Series A convertible preferred stock
that were excluded from the computation of diluted net loss per share of common stock for the three and six months ended June 30, 2026
and 2025, as their effect was anti-dilutive:
Schedule
of Securities Excluded from the Computation of Diluted Net Loss per Common Stock
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three months ended June 30, | | |
Six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Stock options | |
| 26 | | |
| 12 | | |
| 47 | | |
| 12 | |
| Warrants | |
| 841 | | |
| 1 | | |
| 841 | | |
| 1 | |
| Preferred stock converted into common stock | |
| 1 | | |
| - | | |
| 2 | | |
| - | |
| Total potential common shares excluded from computation | |
| 868 | | |
| 13 | | |
| 890 | | |
| 13 | |
|